Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Scinai Immunotherapeutics ( (SCNI) ) has provided an update.
On February 17, 2026, Scinai Immunotherapeutics completed the acquisition of Recipharm Israel Ltd., which operates a cGMP active pharmaceutical ingredient manufacturing site in Yavne, Israel, and signed a long-term strategic commercial collaboration with Recipharm. The deal preserves the Yavne site’s operations and staff while integrating it into Scinai’s CDMO platform alongside its Jerusalem facility.
The acquisition and collaboration materially expand Scinai’s manufacturing footprint and technical scope to cover recombinant proteins, small molecules, peptides, antibodies and oligonucleotides through combined internal and partnered capabilities. By aligning early-stage services at Scinai with Recipharm’s global late-stage and commercial network, including pre-agreed quality and tech transfer frameworks, the arrangement aims to offer clients a seamless end-to-end development pathway and differentiates Scinai among smaller CDMOs, with shared economics as programs advance.
The most recent analyst rating on (SCNI) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Scinai Immunotherapeutics stock, see the SCNI Stock Forecast page.
Spark’s Take on SCNI Stock
According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.
The score is held back primarily by weak financial performance—persistent operating losses and continued cash burn despite recent balance sheet improvement. Technicals are a moderate positive with the stock trading above key short-term averages and mildly positive momentum, while valuation is constrained by a negative P/E and no dividend support.
To see Spark’s full report on SCNI stock, click here.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is an Israel-based biopharmaceutical company focused on developing inflammation and immunology therapeutics while operating a growing contract development and manufacturing organization (CDMO) business. The company offers early-stage development, analytics, and clinical manufacturing services, targeting biopharmaceutical customers seeking integrated development and manufacturing solutions.
Average Trading Volume: 50,048
Technical Sentiment Signal: Sell
Current Market Cap: $635K
See more insights into SCNI stock on TipRanks’ Stock Analysis page.